Synthetic lethal interactions, where mutation of one gene renders cells sensitive to inhibition
of another gene, can be exploited for the development of targeted therapeutics in cancer …

Non–small lung cancers (NSCLC) frequently (∼ 30%) harbor KRAS driver mutations, half of
which are KRAS G12C. KRAS-mutant NSCLC with comutated STK11 and/or KEAP1 is …

In the past two decades, technological advances have brought unprecedented insights into
the paediatric cancer genome revealing characteristics distinct from those of adult cancer …

Dynamic chromatin remodeling requires regulatory mechanisms for its adaptation to
different nuclear function, which are likely to be mediated by signaling proteins. In this …

Background Dynamic chromatin remodeling is associated with changes in the epigenetic
pattern of histone acetylations and methylations required for processes based on dynamic …

Tumor cells can result from gene mutations and over-expression. Synthetic lethality (SL)
offers a desirable setting where cancer cells bearing one mutated gene of an SL gene pair …

Vaccinia-related kinase 1 (VRK1) and the δ and ε isoforms of casein kinase 1 (CK1) are
linked to various disease-relevant pathways. However, the lack of tool compounds for these …

DEAD/H-box helicases are implicated in virtually every aspect of RNA metabolism, including
transcription, pre-mRNA splicing, ribosomes biogenesis, nuclear export, translation …

Nuclear atypia, including altered nuclear size, contour, and chromatin organization, is
ubiquitous in cancer cells. Atypical primary nuclei and micronuclei can rupture during …

In cancer, synthetic lethality refers to the drug-induced inactivation of one gene and the
inhibition of another in cancer cells by a drug, resulting in the death of only cancer cells; …